Common mechanisms and holistic care in atherosclerosis and osteoporosis 11 Medical and Health Sciences 1103 Clinical Sciences

Zoltán Szekanecz, Hennie G. Raterman, Zsófia Petho, Willem F. Lems

Research output: Contribution to journalReview articleAcademicpeer-review

Abstract

Cardiovascular (CV) disease and osteoporosis (OP) have become increasing challenges in the aging population and even more in patients with inflammatory rheumatic diseases, such as rheumatoid arthritis, spondyloarthropathies, and systemic lupus erythematosus. In this review, we discuss how the epidemiology and pathogenesis of CV events and OP are overlapping. Smoking, diabetes mellitus, physical inactivity as conventional risk factors as well as systemic inflammation are among the modifiable risk factors for both CV events and bone loss. In rheumatic patients, systemic "high-grade" inflammation may be the primary driver of accelerated atherogenesis and bone resorption. In the general population, in which some individuals might have low-grade systemic inflammation, a holistic approach to drug treatment and lifestyle modifications may have beneficial effects on the bone as well as the vasculature. In rheumatic patients with accelerated inflammatory atherosclerosis and bone loss, the rapid and effective suppression of inflammation in a treat-to-target regime, aiming at clinical remission, is necessary to effectively control comorbidities.
Original languageEnglish
Article number15
JournalArthritis Research and Therapy
Volume21
Issue number1
DOIs
Publication statusPublished - 2019

Cite this

@article{1dced766f9294f5faa4b5f3147d56d03,
title = "Common mechanisms and holistic care in atherosclerosis and osteoporosis 11 Medical and Health Sciences 1103 Clinical Sciences",
abstract = "Cardiovascular (CV) disease and osteoporosis (OP) have become increasing challenges in the aging population and even more in patients with inflammatory rheumatic diseases, such as rheumatoid arthritis, spondyloarthropathies, and systemic lupus erythematosus. In this review, we discuss how the epidemiology and pathogenesis of CV events and OP are overlapping. Smoking, diabetes mellitus, physical inactivity as conventional risk factors as well as systemic inflammation are among the modifiable risk factors for both CV events and bone loss. In rheumatic patients, systemic {"}high-grade{"} inflammation may be the primary driver of accelerated atherogenesis and bone resorption. In the general population, in which some individuals might have low-grade systemic inflammation, a holistic approach to drug treatment and lifestyle modifications may have beneficial effects on the bone as well as the vasculature. In rheumatic patients with accelerated inflammatory atherosclerosis and bone loss, the rapid and effective suppression of inflammation in a treat-to-target regime, aiming at clinical remission, is necessary to effectively control comorbidities.",
author = "Zolt{\'a}n Szekanecz and Raterman, {Hennie G.} and Zs{\'o}fia Petho and Lems, {Willem F.}",
year = "2019",
doi = "10.1186/s13075-018-1805-7",
language = "English",
volume = "21",
journal = "Arthritis Research & Therapy",
issn = "1478-6354",
publisher = "BioMed Central",
number = "1",

}

Common mechanisms and holistic care in atherosclerosis and osteoporosis 11 Medical and Health Sciences 1103 Clinical Sciences. / Szekanecz, Zoltán; Raterman, Hennie G.; Petho, Zsófia; Lems, Willem F.

In: Arthritis Research and Therapy, Vol. 21, No. 1, 15, 2019.

Research output: Contribution to journalReview articleAcademicpeer-review

TY - JOUR

T1 - Common mechanisms and holistic care in atherosclerosis and osteoporosis 11 Medical and Health Sciences 1103 Clinical Sciences

AU - Szekanecz, Zoltán

AU - Raterman, Hennie G.

AU - Petho, Zsófia

AU - Lems, Willem F.

PY - 2019

Y1 - 2019

N2 - Cardiovascular (CV) disease and osteoporosis (OP) have become increasing challenges in the aging population and even more in patients with inflammatory rheumatic diseases, such as rheumatoid arthritis, spondyloarthropathies, and systemic lupus erythematosus. In this review, we discuss how the epidemiology and pathogenesis of CV events and OP are overlapping. Smoking, diabetes mellitus, physical inactivity as conventional risk factors as well as systemic inflammation are among the modifiable risk factors for both CV events and bone loss. In rheumatic patients, systemic "high-grade" inflammation may be the primary driver of accelerated atherogenesis and bone resorption. In the general population, in which some individuals might have low-grade systemic inflammation, a holistic approach to drug treatment and lifestyle modifications may have beneficial effects on the bone as well as the vasculature. In rheumatic patients with accelerated inflammatory atherosclerosis and bone loss, the rapid and effective suppression of inflammation in a treat-to-target regime, aiming at clinical remission, is necessary to effectively control comorbidities.

AB - Cardiovascular (CV) disease and osteoporosis (OP) have become increasing challenges in the aging population and even more in patients with inflammatory rheumatic diseases, such as rheumatoid arthritis, spondyloarthropathies, and systemic lupus erythematosus. In this review, we discuss how the epidemiology and pathogenesis of CV events and OP are overlapping. Smoking, diabetes mellitus, physical inactivity as conventional risk factors as well as systemic inflammation are among the modifiable risk factors for both CV events and bone loss. In rheumatic patients, systemic "high-grade" inflammation may be the primary driver of accelerated atherogenesis and bone resorption. In the general population, in which some individuals might have low-grade systemic inflammation, a holistic approach to drug treatment and lifestyle modifications may have beneficial effects on the bone as well as the vasculature. In rheumatic patients with accelerated inflammatory atherosclerosis and bone loss, the rapid and effective suppression of inflammation in a treat-to-target regime, aiming at clinical remission, is necessary to effectively control comorbidities.

UR - https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=85059801605&origin=inward

UR - https://www.ncbi.nlm.nih.gov/pubmed/30630495

U2 - 10.1186/s13075-018-1805-7

DO - 10.1186/s13075-018-1805-7

M3 - Review article

VL - 21

JO - Arthritis Research & Therapy

JF - Arthritis Research & Therapy

SN - 1478-6354

IS - 1

M1 - 15

ER -